...reports. Favorable currency exchange rates boosted revenue by 5 percent for Merck & Co. and by 7.6 percent for Schering-Plough Corp. Schering also noted that about 70 percent of its sales came from outside the country. And both Wyeth and Johnson & Johnson,...

...two weeks. Favorable currency exchange rates boosted revenue by 5 percent for Merck & Co. and by 7.6 percent for Schering-Plough Corp. Schering also noted that about 70 percent of its sales came from outside the country. And both Wyeth and Johnson & Johnson,...

...a new study of cholesterol drug Vytorin are "likely to be an anomaly" unrelated to the drug, makers Merck & Co and Schering-Plough Corp said in a letter to doctors. The study called SEAS found a higher incidence of cancer among patients who took Vytorin compared...

...center to develop veterinary vaccines in Belgium and the purchase of several vaccines and veterinary medicines from Schering-Plough Corp. in April. It also got U.S. approval for a new antibiotic for cats and dogs, Convenia, a one-time injection for common...

...doesn't lower the risk of major heart problems, according to a study released yesterday by the drug's manufacturers, Schering-Plough Corp. and Merck & Co. The study of 1,873 people found that Vytorin, a pill that combines the cholesterol-lowering medications...

...earnings and oil prices. I expect more of the same." The market was also uneasy about drug makers Merck & Co. and Schering-Plough Corp. Both pharmaceutical companies fell after a new study showed their cholesterol drug Vytorin did not meet its main goals....

...of $903.3 million, according to FactSet Research. See full story. The company was cut to sell from hold at Citi. Schering-Plough Corp. (SGP: , , ) reported second-quarter earnings fell to $398 million, or 24 cents a share, from $517 million, or 34 cents,...

...new study found, Vytorin sold by Merck & Co Inc and Schering-Plough Corp, used for the treatment of high cholesterol, failed to prevent the worsening of cholesterol disease or to lower the need for surgery in those patients with heart valve disease. The often...

...said Jim Herrick, manager of equity trading at Baird & Co. The market also was uneasy about drugmakers Merck & Co. and Schering-Plough Corp. Both pharmaceutical companies fell after a new study showed their cholesterol drug Vytorin did not meet its main goals. The...

... Schering-Plough Corp.'s second-quarter profit tumbled 23 percent on charges for a canceled development program with Merck & Corp. and accounting adjustments, but adjusted profit topped Wall Street forecast. The Kenilworth, New Jersey-based drug developer...